全文获取类型
收费全文 | 346篇 |
免费 | 48篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 15篇 |
妇产科学 | 4篇 |
基础医学 | 29篇 |
口腔科学 | 13篇 |
临床医学 | 65篇 |
内科学 | 79篇 |
皮肤病学 | 9篇 |
神经病学 | 20篇 |
特种医学 | 65篇 |
外科学 | 41篇 |
综合类 | 3篇 |
预防医学 | 10篇 |
眼科学 | 5篇 |
药学 | 7篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2024年 | 1篇 |
2023年 | 13篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 5篇 |
2019年 | 4篇 |
2018年 | 9篇 |
2017年 | 12篇 |
2016年 | 16篇 |
2015年 | 11篇 |
2014年 | 17篇 |
2013年 | 25篇 |
2012年 | 16篇 |
2011年 | 13篇 |
2010年 | 12篇 |
2009年 | 26篇 |
2008年 | 12篇 |
2007年 | 8篇 |
2006年 | 8篇 |
2005年 | 8篇 |
2004年 | 2篇 |
2003年 | 8篇 |
2002年 | 1篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 15篇 |
1997年 | 12篇 |
1996年 | 14篇 |
1995年 | 5篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 5篇 |
1989年 | 11篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 5篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1975年 | 1篇 |
排序方式: 共有396条查询结果,搜索用时 25 毫秒
1.
Oral lichenoid drug eruptions 总被引:1,自引:0,他引:1
OBJECTIVES: To identify, from amongst drugs reported as causing lichenoid drug eruptions, those affecting the oral mucous membranes and to review the clinical, histo-logical and immunological features of such oral lichenoid drug eruptions in comparison to oral lichen planus, amalgam contact lesions and lichen planus-like eruption in graft-versus-host disease (GVHD).
DATA SOURCES: Ovid® Medline data searches on CD-Rom were carried out for the years 1966–1996 to identify reports of oral lichenoid drug eruptions and their clinical, histological and immunological featureS. Articles retrieved were examined for further appropriate references in the period 1940–1996.
DATA EXTRACTION AND SYNTHESIS: Each paper was critically examined for evidence of a clinically verifiable lichenoid drug eruption affecting the oral mucous membranes and the effects of subsequent drug withdrawal. Available clinical, histological and immunological features were recorded. The papers examined were too diverse in nature to permit a structured criticism. The extracted data have been tabulated where appropriate.
CONCLUSIONS: The reports of oral lichenoid drug eruptions are considerably fewer than those of cutaneous eruptions and fewer drugs have been reported as causing oral rather than cutaneous lichenoid eruptionS. Histology and immunology cannot be used reliably to differentiate lichenoid drug eruptions from idiopathic lichen planus, amalgam contact lesions and lichen planus-like eruption in GVHD. Lichenoid drug eruptions may also show some histological characteristics of oral discoid lupus erythematosuS. An accepted protocol agreed by a number of international centres would permit the gathering of substantial information on LDE and could lead to a greater understanding of the mechanisms involved. 相似文献
DATA SOURCES: Ovid® Medline data searches on CD-Rom were carried out for the years 1966–1996 to identify reports of oral lichenoid drug eruptions and their clinical, histological and immunological featureS. Articles retrieved were examined for further appropriate references in the period 1940–1996.
DATA EXTRACTION AND SYNTHESIS: Each paper was critically examined for evidence of a clinically verifiable lichenoid drug eruption affecting the oral mucous membranes and the effects of subsequent drug withdrawal. Available clinical, histological and immunological features were recorded. The papers examined were too diverse in nature to permit a structured criticism. The extracted data have been tabulated where appropriate.
CONCLUSIONS: The reports of oral lichenoid drug eruptions are considerably fewer than those of cutaneous eruptions and fewer drugs have been reported as causing oral rather than cutaneous lichenoid eruptionS. Histology and immunology cannot be used reliably to differentiate lichenoid drug eruptions from idiopathic lichen planus, amalgam contact lesions and lichen planus-like eruption in GVHD. Lichenoid drug eruptions may also show some histological characteristics of oral discoid lupus erythematosuS. An accepted protocol agreed by a number of international centres would permit the gathering of substantial information on LDE and could lead to a greater understanding of the mechanisms involved. 相似文献
2.
3.
4.
van der Kallen CJ Cantor RM van Greevenbroek MM Geurts JM Bouwman FG Aouizerat BE Allayee H Buurman WA Lusis AJ Rotter JI de Bruin TW 《International journal of obesity (2005)》2000,24(11):1381-1391
OBJECTIVE: To search for novel genes contributing to adiposity in familial combined hyperlipidemia (FCH), a disorder characterized by abdominal obesity, hyperlipidemia and insulin resistance, using a 10cM genome-wide scan. DESIGN: Plasma leptin and soluble tumor necrosis factor receptor superfamily members 1A and 1B (sTNFRSF1A and sTNFRSF1B, also known as sTNFR1 and sTNFR2) were analyzed as unadjusted and adjusted quantitative phenotypes of adiposity, in addition to body mass index (BMI), in multipoint and single-point analyses. In the second stage of analysis, an important chromosome 1 positional candidate gene, the leptin receptor (LEPR), was studied. SUBJECTS: Eighteen Dutch pedigrees with familial combined hyperlipidemia (FCH) (n= 198) were analyzed to search for chromosomal regions harboring genes contributing to adiposity. RESULTS: Multipoint analysis of the genome scan data identified linkage (log of odds, LOD, 3.4) of leptin levels to a chromosomal region defined by D1S3728 and D1S1665, flanking the leptin receptor (LEPR) gene by approximately 9 and 3 cM, respectively. The LOD score decreased to 1.8 with age- and gender-adjusted leptin levels. Notably, BMI also mapped to this region with an LOD score of 1.2 (adjusted BMI: LOD 0.5). Two polymorphic DNA markers in LEPR and their haplotypes revealed linkage to unadjusted and adjusted BMI and leptin, and an association with leptin levels was found as well. In addition, the marker D8S1110 showed linkage (LOD 2.8) with unadjusted plasma concentrations of soluble TNFRSF1A. BMI gave a LOD score of 0.6. Moreover, a chromosome 10 q-ter locus, AFM198ZB, showed linkage with adjusted BMI (LOD 3.3). CONCLUSION: These data provide evidence that a human chromosome 1 locus, harboring the LEPR gene, contributes to plasma leptin concentrations, adiposity and body weight in humans affected with this insulin resistant dyslipidemic syndrome. Novel loci on chromosome 8 and 10 qter need further study. 相似文献
5.
6.
Professor John Humphrey BE MD FRCP FRS 《Medicine, conflict, and survival》2013,29(3):165-166
The Medical Association for Prevention of War (UK) submitted the following written statement to the Third Special Session on Disarmament of the United Nations General Assembly, which was held at UN headquarters in New York on 31 May‐25 June 1988. 相似文献
7.
8.
Gian Paolo Fadini MD Mario Luca Morieri MD Enrico Longato BE Benedetta Maria Bonora MD Silvia Pinelli MD Elisa Selmin MD Giacomo Voltan MD Daniele Falaguasta MD Silvia Tresso MD Giorgia Costantini MD Giovanni Sparacino PhD Barbara Di Camillo PhD Lara Tramontan PhD Anna Maria Cattelan MD Andrea Vianello MD Paola Fioretto MD Roberto Vettor MD Angelo Avogaro MD 《Diabetes, obesity & metabolism》2020,22(10):1946-1950
Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19. 相似文献
9.
Bani Tamraz Lori Reisner Audrey L. French Samuel T. King Margaret A. Fischl Igho Ofotokun Angela Kashuba Joel Milam Kerry Murphy Michael Augenbraun Chenglong Liu Patrick R. Finley Bradley Aouizerat Jennifer Cocohoba Stephen Gange Peter Bacchetti Ruth M. Greenblatt 《Pharmacotherapy》2019,39(9):899-911
10.
Over an average span of one year, we performed a prospective clinical and immunologic evaluation of 30 patients with hemophilia. No patient developed life-threatening opportunistic infection or malignancy; however, the immunologic abnormalities and lymphadenopathy initially present in nine patients (lymphadenopathy group) persisted. In addition, five patients, representing 24% of the initial group without lymphadenopathy, developed generalized lymphadenopathy (converter group). One episode of idiopathic thrombocytopenia (ITP) and one episode of staphylococcal sepsis occurred in this "converter" group; one episode of ITP also occurred in the lymphadenopathy group. Sixteen patients remained asymptomatic. At the time of the follow-up evaluation, those differences in mononuclear cell (MNC) percentages and numbers noted initially among the three hemophiliac groups were no longer present. Natural killer cell function alone or in the presence of biologic response modifiers was not different among hemophiliac and control groups. Before developing lymphadenopathy, the converter group of patients had significantly better lymphocyte mitogenic function than did the other two groups of patients with hemophilia. However, lymphocyte mitogenic responses of all groups of patients with hemophilia significantly deteriorated over the course of the study. The abnormal mitogenic responses noted in these patients was explained in part by higher levels of spontaneous suppressor cell activity in mononuclear cell preparations from patients with hemophilia. We conclude that long-term immunologic studies of this patient population requires both quantitative and qualitative evaluations. Our data show that patients with hemophilia have progressive dysfunction of cell- mediated immunity. 相似文献